Company Description
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure.
In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths.
The company is based in Sunnyvale, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Peter A. Altman Ph.D. |
Contact Details
Address: 320 Soquel Way Sunnyvale, California 94085 United States | |
| Phone | 650-226-0123 |
| Website | biocardia.com |
Stock Details
| Ticker Symbol | BCDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000925741 |
| CUSIP Number | 09060U507 |
| ISIN Number | US09060U5074 |
| Employer ID | 23-2753988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter A. Altman Ph.D. | Chief Executive Officer, President and Director |
| David McClung | Chief Financial Officer |
| Edward M. Gillis | Senior Vice President of Devices |
| Dr. Sujith Shetty MBBS | Chief Medical Officer and Vice President of Clinical and Regulatory |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 1, 2024 | EFFECT | Notice of Effectiveness |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 8-K | Current Report |